Findings from a prospective phase 2 clinical trial show that isatuximab (Sarclisa), an anti-CD38 monoclonal antibody, is an effective and well-tolerated treatment for patients with relapsed and/or refractory systemic light chain (AL)…
Isatuximab Shows Efficacy, Safety in R/R Systemic Light Chain Amyloidosis | Targeted Oncology
